---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307296"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:31:16.277095+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma appoints Lynn Seely as President and CEO, succeeding Elizabeth Homans

## Summary
- Elizabeth Homans steps down as CEO effective Dec 15, 2022; will remain as consultant through June 2024.
- Homans receives $900k base salary severance (18 months), $360k target bonus, continued option vesting, COBRA.
- Lynn Seely appointed President and CEO; annual base salary $650k, target bonus 60%, and option for 7.5M shares.
- Seely previously CEO of Myovant Sciences and CMO of Medivation; joined Lyell Board in May 2021.

## SEC filing metadata
- accession: 0001193125-22-307296
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/d438667d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307296
- JSON: https://secwatch.observer/filing/0001193125-22-307296.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307296.txt

## Key facts
- Executive change
  Elizabeth Homans resigned as Chief Executive Officer at Lyell Immunopharma, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm
- Executive change
  Lynn Seely was appointed as President and Chief Executive Officer at Lyell Immunopharma, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312522307296/0001193125-22-307296-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.